2022年美國癌症研究協會（AACR）年會即將於4月8-13日在美國New Orleans召開。尊龙凯时人生就是搏官网將在會議上公布多項自主研發全人單抗、雙抗、雙抗ADC新藥的研究成果，以及創新動物模型在藥物評價中的應用研究，並在會議現場設立展台#1043。

一、多項新藥研究及技術平台成果：

1.TNFR2非阻斷型全人抗體藥物（1C3）

標題：1C3, a Novel Non-blocking Anti-human TNFR2 Antibody Generated From RenMice, Exhibits Promising Anti-tumor Activity and Safety in Syngeneic Tumor Models in Humanized TNFR2 Mice

話題：Immunology

編號：2907

展示時間：Tuesday, April 12th 9:00 AM-12:30 PM Poster Session

簡介：1C3是一款新型TNFR2非阻斷治療抗體，能夠促進CD8+ T細胞增殖，增加腫瘤微環境中效應T細胞的比例。該藥物由尊龙凯时人生就是搏官网與寶船生物合作開發，經尊龙凯时人生就是搏官网自主研發RenMice小鼠進行抗體發現，B-hTNFR2小鼠體內高通量篩選獲得。臨床前研究表明1C3單藥及與PD-1或PD-L1抗體聯用在小鼠腫瘤模型中均有良好的抗腫瘤活性。

2.Her2-Trop2全人雙抗ADC（YH012）

標題：YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy

話題：Immunology

編號：4256

展示時間：Wednesday, April 13th 9:00 AM-12:30 PM Poster Session

簡介：YH012是一款尊龙凯时人生就是搏官网自主研發的HER2-TROP2全人雙特異性抗體偶聯藥物（雙抗ADC）。HER2與TROP2在胃癌、結直腸癌、膀胱癌和乳腺癌等多種腫瘤上共表達。臨床前研究中，HER2-TROP2 BsAb與母本單抗相比增加了內吞活性，而單價HER2或TROP2單抗內吞活性降低，YH012較單抗HER2/TROP2-ADC具有更強的體外細胞殺傷活性。YH012在非小細胞肺癌和胃癌CDX小鼠模型體內均顯示出良好的抗腫瘤活性。

3.PD-1-CD40 雙特異性抗體（YH008）

標題：YH008, a PD-1-CD40 Bispecific Antibody, Inhibits Tumor Growth In Vivo Through PD-1-Dependent Activation of CD40 Signaling

話題： Immunology

編號： 5615

展示形式：E-Poster

簡介：YH008是一款抗PD-1/CD40 Fc沉默的IgG1亞型雙特異性抗體。臨床前研究中，YH008在B-hPD-1/CD40小鼠B16F10腫瘤模型中顯示出劑量依賴的抗腫瘤活性，該抗體以PD-1依賴的方式激活CD40，促進樹突細胞增殖和活化，增加腫瘤浸潤CD8+ T細胞/Treg細胞比率。在100 mg/kg的高劑量下，YH008未升高B-hPD1/hCD40小鼠血液中的肝酶。同樣，在食蟹猴劑量遞增研究中未觀察到顯著不良事件。YH008目前處於臨床前開發階段，預計於2022年遞交IND申請。

4. 新型TCRm抗體藥物開發平台

標題：Generation of TCR-like fully human antibodies against HLA-antigen-peptide complexes using HLA transgenic RenMice

話題：Therapeutic antibodies

編號：2885

簡介：尊龙凯时人生就是搏官网建立了基於HLA/RenMice小鼠的TCRm抗體開發平台，能夠很好的針對胞內抗原靶點進行高通量的TCRm抗體開發，較天然TCR相比，TCRm抗體具有更高的親和力和特異性。

5.規模化抗體新藥開發-“千鼠萬抗”計劃（RenMice HiTS Platform）

標題：Identifying New Therapeutic Antibodies Using Knockout Mice Expressing Human Immunoglobulin Variable Domain Genes

話題：Experimental and Molecular Therapeutics

編號： 1891

二、BioMice人源化動物模型在新藥臨床前評價應用研究：

Sunday, April 10th 1:30-5:00 PM Poster Session

1.B-hGLPR Mice

#3:Developing a Translational Tool for GLP-1-Based Therapeutic Agonists in Humanized GLP1R Mice

2.B-hTFR1 Mice

#377:Evaluating Delivery of TFR1-targeting Therapies to the CNS in a Novel Humanized TFR1 Mouse Model

Monday, April 11th 1:30-5:00 PM Poster Session

3. B-hIL21R Mice and B-hPD-1/hIL21R Mice

#1641:Evaluating In Vivo Efficacy of Bi-Functional Fusion Protein Anti-PD-1-IL21 in Humanized B-hIL21R Mice and B-hPD-1/hIL21R Mice

4. B-hVSIG4 Mice

#1642:Evaluating In Vivo Efficacy of Anti-VSIG4 Antibodies in Humanized B-hVSIG4 Mice

5. B-hIL12A/hIL12B/hIL12RB1/hIL12RB2 Mice

#1643:B-hIL12A/hIL12B/hIL12RB1/hIL12RB2: A Novel Animal Model for Generation of IL12 Therapies

6.B-hGARP Mice

#1644:Generation and Validation of Humanized GARP Mice for Testing Novel Anti-Human GARP Antibodies

7.B-hCD16A Mice

#1645:Advancing the Development of CD16A-Based Bispecific Antibodies in Humanized CD16A Mouse Models

8.B-hTROP2 Mice

#1646:Humanized TROP2 Mice Provide a Preclinical Tool for the Evaluation of Therapeutic Drugs Targeting TROP2

9. B-hCSF1/hCSF1R Mice

#1648:Evaluation of Therapeutic Drug Candidates Using a Novel Humanized B-hCSF1/hCSF1R

10. B-hPVRIG Mice

#1649:Humanized PVRIG Mice: A Novel Tool for Evaluating Anti-PVRIG Immunotherapies

11.B-hTLR8 Mice

#1651:Generation of a Novel Humanized TLR8 Mouse Model for the Evaluation of Human TLR8 Agonists and Antibody-Conjugated TLR8 Agonists

12.B-hB7-H4 Mice

#1652:A Humanized Mouse Model of the Promising Immune Checkpoint Molecule B7-H4

13. B-HLA-A2.1 Mice

#1992:Evaluating In Vivo Efficacy of Peptide Vaccines in Humanized B-HLA-A2.1 Mice

14. B-hTSLP/hTSLPR Mice

#2089:Functional Analysis of Anti-TSLP Antibodies Using Humanized B-hTSLP/hTSLPR Mice

15.B-hIL36R Mice

#2090:Humanized IL36R Mice Provide a Preclinical Tool for the Evaluation of Therapeutic Drugs Targeting IL36R